A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma.
Nicola Silvestris,Hector Soto Parra,Francesco Angelini,Serena Di Cosimo,Modesto D'Aprile,Armando Santoro +5 more
TL;DR: The case described here is the fifth case reported in the literature of advanced c-kit-positive leiomyosarcoma treated with imatinib mesylate after combination therapy with epirubicin and ifosfamide had failed.
Journal ArticleDOI
Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)
Margaretha G.M. Roemer,Azra H. Ligon,Andreas Engert,Anas Younes,Armando Santoro,Pier Luigi Zinzani,John M. Timmerman,Stephen M. Ansell,Philippe Armand,Michelle A. Fanale,Voravit Ratanatharathorn,John Kuruvilla,Jonathon B. Cohen,Graham P. Collins,Kerry J. Savage,Marek Trneny,Donna Neuberg,Robert A. Redd,Benedetto Farsaci,Kazunobu Kato,Anne Sumbul,Scott J. Rodig,Margaret A. Shipp +22 more
TL;DR: CheckMate205 is a multicenter, multicohort, phase 2 trial of nivo in R/R cHL and there was a significant association between PD-L1 protein expression (H-score) and the level of 9p24.1 alterations and PD- L1 H-scores and the association of these alterations with clinical outcome was assessed.
Journal ArticleDOI
Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).
Sandrine Faivre,Armando Santoro,Robin Katie Kelley,Philippe Merle,Edward Gane,Jean-Yves Douillard,Dirk Waldschmidt,Mary F. Mulcahy,Charlotte Costentin,Beatriz Minguez,Pasqua Papappicco,Ivelina Gueorguieva,Ann Cleverly,Durisala Desaiah,Michael Lahn,Nicola Murray,Karim A. Benhadji,Eric Raymond,Gianluigi Giannelli +18 more
TL;DR: The safety and antitumor activity of LY in HCC patients with elevated AFP in this ongoing study is reported, with positive results for time-to-progression and biomarker changes for each dose.
Proceedings ArticleDOI
Abstract CT149: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Kupit,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +22 more
TL;DR: Treatment of patients with relapsed or refractory indolent B-cell lymphoma with copanlisib resulted in durable tumor responses and a manageable safety profile, withLow rates of severe hepatic enzymopathy, diarrhea or inflammatory events, as well as low rates of opportunistic infections, fatal infections or other fatal serious adverse events.
Journal ArticleDOI
O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD
Gianluigi Giannelli,Sandrine Faivre,Armando Santoro,Robin Katie Kelley,Philippe Merle,Edward Gane,J.-Y. Douillard,D. Waldschmidt,Mary F. Mulcahy,Charlotte Costentin,Beatriz Minguez,P.P. Papappicco,Ivelina Gueorguieva,Ann Cleverly,D. Desaiah,M.M. Lahn,S. Ameryckx,K.A. Benhadji,Eric Raymond +18 more